Symbols / SILO Stock $0.44 -1.62% Silo Pharma, Inc.
SILO (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Ratings
Current target
$0.44
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-28 | init | Laidlaw & Co. | — → Buy | $10 |
- Washington speeds psychedelic PTSD work as Silo spotlights program - Stock Titan Wed, 29 Apr 2026 13
- Why did SILO stock soar 85% today? - MSN Sun, 26 Apr 2026 01
- Why Did SILO Stock Soar 85% Today? - Stocktwits ue, 07 Apr 2026 07
- SILO Price Today: Silo Pharma, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange Sat, 25 Apr 2026 23
- Silo Pharma stock surges on European patent approval - Investing.com ue, 07 Apr 2026 07
- 12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga Mon, 27 Apr 2026 17
- Silo Pharma Secures European Patent Approval for Preventative Therapy Targeting 5-HT4 Pathway in Stress-Related Disorders | SILO Stock News - Quiver Quantitative Mon, 06 Apr 2026 07
- Europe moves to protect Silo's therapy aimed at preventing stress disorders - Stock Titan Mon, 06 Apr 2026 07
- CMND stock set for biggest intraday gains in over three years — here’s why retail is eyeing further upside - MSN Sun, 26 Apr 2026 01
- Silo Pharma stock surges on $1M share buyback program - Investing.com Mon, 23 Feb 2026 08
- After Trump's psychedelics order, Silo spotlights intranasal PTSD drug - Stock Titan Mon, 20 Apr 2026 07
- A biotech advancing a PTSD drug just bought an AI agent platform - Stock Titan Wed, 22 Apr 2026 07
- [EFFECT] Silo Pharma, Inc. SEC Filing - Stock Titan Wed, 15 Apr 2026 07
- Silo Pharma (NASDAQ: SILO) registers 5.02M shares underlying warrants; $0.60 strike - Stock Titan hu, 16 Apr 2026 07
- Silo Pharma (NASDAQ: SILO) issues 2.1M shares for QwikAgents software deal - Stock Titan hu, 02 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
|
| Operating Revenue |
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
|
| Cost Of Revenue |
|
0.04
+658.74%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Reconciled Cost Of Revenue |
|
0.04
+658.74%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Gross Profit |
|
0.03
-58.04%
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
|
| Operating Expense |
|
4.31
-9.71%
|
4.77
+21.68%
|
3.92
+5.60%
|
3.71
|
| Research And Development |
|
2.16
-8.75%
|
2.37
+180.22%
|
0.85
-34.31%
|
1.29
|
| Selling General And Administration |
|
2.15
-10.66%
|
2.40
-21.87%
|
3.08
+26.75%
|
2.43
|
| General And Administrative Expense |
|
2.15
-10.66%
|
2.40
-21.87%
|
3.08
+26.75%
|
2.43
|
| Salaries And Wages |
|
0.83
-8.43%
|
0.91
+4.03%
|
0.87
+50.89%
|
0.58
|
| Other Gand A |
|
1.32
-12.00%
|
1.50
-32.11%
|
2.21
+27.91%
|
1.72
|
| Total Expenses |
|
4.35
-8.90%
|
4.78
+21.64%
|
3.93
+5.59%
|
3.72
|
| Operating Income |
|
-4.28
+9.03%
|
-4.71
-22.05%
|
-3.86
-5.70%
|
-3.65
|
| Total Operating Income As Reported |
|
-4.28
+9.03%
|
-4.71
-22.05%
|
-3.86
-6.28%
|
-3.63
|
| EBITDA |
|
-4.18
+4.63%
|
-4.38
-20.83%
|
-3.63
+7.14%
|
-3.91
|
| Normalized EBITDA |
|
-4.08
+6.67%
|
-4.37
-26.30%
|
-3.46
+3.30%
|
-3.58
|
| Reconciled Depreciation |
|
0.01
+84.96%
|
0.01
|
0.00
|
—
|
| EBIT |
|
-4.19
+4.50%
|
-4.39
-21.00%
|
-3.63
+7.14%
|
-3.91
|
| Total Unusual Items |
|
-0.10
-578.89%
|
-0.02
+90.97%
|
-0.17
+48.77%
|
-0.33
|
| Total Unusual Items Excluding Goodwill |
|
-0.10
-578.89%
|
-0.02
+90.97%
|
-0.17
+48.77%
|
-0.33
|
| Special Income Charges |
|
-0.04
|
0.00
+100.00%
|
-0.17
-930.17%
|
0.02
|
| Other Special Charges |
|
—
|
—
|
0.17
|
—
|
| Impairment Of Capital Assets |
|
0.04
|
0.00
|
—
|
—
|
| Write Off |
|
—
|
—
|
0.00
+100.00%
|
-0.02
|
| Net Income |
|
-4.23
+3.76%
|
-4.39
-18.70%
|
-3.70
+5.32%
|
-3.91
|
| Pretax Income |
|
-4.23
+3.76%
|
-4.39
-20.98%
|
-3.63
+7.07%
|
-3.91
|
| Net Non Operating Interest Income Expense |
|
0.16
-52.26%
|
0.33
-16.66%
|
0.39
+458.88%
|
0.07
|
| Interest Expense Non Operating |
|
0.04
+633.71%
|
0.01
+4.42%
|
0.00
+121.42%
|
0.00
|
| Net Interest Income |
|
0.16
-52.26%
|
0.33
-16.66%
|
0.39
+458.88%
|
0.07
|
| Interest Expense |
|
0.04
+633.71%
|
0.01
+4.42%
|
0.00
+121.42%
|
0.00
|
| Interest Income Non Operating |
|
0.19
-41.80%
|
0.33
-16.40%
|
0.40
+448.66%
|
0.07
|
| Interest Income |
|
0.19
-41.80%
|
0.33
-16.40%
|
0.40
+448.66%
|
0.07
|
| Other Income Expense |
|
-0.10
-578.89%
|
-0.02
+90.97%
|
-0.17
+48.77%
|
-0.33
|
| Gain On Sale Of Security |
|
-0.06
-317.44%
|
-0.02
-389.64%
|
-0.00
+99.11%
|
-0.35
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-4.23
+3.76%
|
-4.39
-18.70%
|
-3.70
+5.32%
|
-3.91
|
| Net Income From Continuing Operation Net Minority Interest |
|
-4.23
+3.76%
|
-4.39
-20.98%
|
-3.63
+7.07%
|
-3.91
|
| Net Income From Continuing And Discontinued Operation |
|
-4.23
+3.76%
|
-4.39
-18.70%
|
-3.70
+5.32%
|
-3.91
|
| Net Income Continuous Operations |
|
-4.23
+3.76%
|
-4.39
-20.98%
|
-3.63
+7.07%
|
-3.91
|
| Net Income Discontinuous Operations |
|
—
|
0.00
+100.00%
|
-0.07
-5884.52%
|
-0.00
|
| Normalized Income |
|
-4.12
+5.79%
|
-4.38
-26.45%
|
-3.46
+3.22%
|
-3.58
|
| Net Income Common Stockholders |
|
-4.23
+3.76%
|
-4.39
-18.70%
|
-3.70
+5.32%
|
-3.91
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
0.00
|
| Diluted EPS |
|
—
|
-1.19
+0.83%
|
-1.20
+29.82%
|
-1.71
|
| Basic EPS |
|
—
|
-1.19
+0.83%
|
-1.20
+29.82%
|
-1.71
|
| Basic Average Shares |
|
—
|
3.68
+19.50%
|
3.08
+34.83%
|
2.28
|
| Diluted Average Shares |
|
—
|
3.68
+19.50%
|
3.08
+34.83%
|
2.28
|
| Diluted NI Availto Com Stockholders |
|
-4.23
+3.76%
|
-4.39
-18.70%
|
-3.70
+5.32%
|
-3.91
|
| Insurance And Claims |
|
—
|
—
|
0.09
-29.30%
|
0.13
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets |
|
7.41
-4.32%
|
7.75
|
| Current Assets |
|
7.11
-7.42%
|
7.68
|
| Cash Cash Equivalents And Short Term Investments |
|
7.08
-7.63%
|
7.67
|
| Cash And Cash Equivalents |
|
3.91
+10.82%
|
3.52
|
| Other Short Term Investments |
|
3.17
-23.33%
|
4.14
|
| Receivables |
|
—
|
0.00
|
| Accrued Interest Receivable |
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
| Assets Held For Sale Current |
|
—
|
—
|
| Other Current Assets |
|
0.03
+93.84%
|
0.02
|
| Total Non Current Assets |
|
0.30
+362.21%
|
0.06
|
| Goodwill And Other Intangible Assets |
|
0.24
|
0.00
|
| Other Intangible Assets |
|
0.24
|
—
|
| Non Current Prepaid Assets |
|
—
|
—
|
| Other Non Current Assets |
|
0.06
-8.98%
|
0.06
|
| Total Liabilities Net Minority Interest |
|
2.38
+51.51%
|
1.57
|
| Current Liabilities |
|
1.66
+113.51%
|
0.78
|
| Payables And Accrued Expenses |
|
1.58
+125.15%
|
0.70
|
| Payables |
|
—
|
—
|
| Accounts Payable |
|
—
|
—
|
| Current Deferred Liabilities |
|
0.07
+0.00%
|
0.07
|
| Current Deferred Revenue |
|
0.07
+0.00%
|
0.07
|
| Total Non Current Liabilities Net Minority Interest |
|
0.72
-9.08%
|
0.79
|
| Non Current Deferred Liabilities |
|
0.72
-9.08%
|
0.79
|
| Non Current Deferred Revenue |
|
0.72
-9.08%
|
0.79
|
| Stockholders Equity |
|
5.03
-18.50%
|
6.18
|
| Common Stock Equity |
|
5.03
-18.50%
|
6.18
|
| Capital Stock |
|
0.00
+42.09%
|
0.00
|
| Common Stock |
|
0.00
+42.09%
|
0.00
|
| Preferred Stock |
|
—
|
0.00
|
| Share Issued |
|
4.48
+41.95%
|
3.16
|
| Ordinary Shares Number |
|
4.48
+54.30%
|
2.91
|
| Treasury Shares Number |
|
0.00
-100.00%
|
0.25
|
| Additional Paid In Capital |
|
20.30
+15.81%
|
17.53
|
| Retained Earnings |
|
-15.26
-40.41%
|
-10.87
|
| Gains Losses Not Affecting Retained Earnings |
|
0.00
+138.85%
|
-0.01
|
| Treasury Stock |
|
0.00
-100.00%
|
0.47
|
| Other Equity Adjustments |
|
0.00
+138.85%
|
-0.01
|
| Total Equity Gross Minority Interest |
|
5.03
-18.50%
|
6.18
|
| Total Capitalization |
|
5.03
-18.50%
|
6.18
|
| Working Capital |
|
5.46
-21.00%
|
6.91
|
| Invested Capital |
|
5.03
-18.50%
|
6.18
|
| Net Tangible Assets |
|
4.79
-22.40%
|
6.18
|
| Tangible Book Value |
|
4.79
-22.40%
|
6.18
|
| Non Current Note Receivables |
|
—
|
—
|
| Notes Receivable |
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-4.66
-21.58%
|
-3.83
-18.90%
|
-3.22
+7.81%
|
-3.50
|
| Cash Flow From Continuing Operating Activities |
|
-4.66
-21.58%
|
-3.83
-18.90%
|
-3.22
+7.81%
|
-3.50
|
| Cash From Discontinued Operating Activities |
|
—
|
—
|
—
|
0.00
|
| Net Income From Continuing Operations |
|
-4.23
+3.76%
|
-4.39
-18.70%
|
-3.70
+5.32%
|
-3.91
|
| Depreciation Amortization Depletion |
|
0.01
+84.96%
|
0.01
|
0.00
|
—
|
| Amortization Cash Flow |
|
0.01
+84.96%
|
0.01
|
0.00
|
—
|
| Depreciation And Amortization |
|
0.01
+84.96%
|
0.01
|
0.00
|
—
|
| Amortization Of Intangibles |
|
0.01
+84.96%
|
0.01
|
0.00
|
—
|
| Other Non Cash Items |
|
0.52
|
—
|
0.09
+205.06%
|
-0.09
|
| Stock Based Compensation |
|
0.12
|
0.00
-100.00%
|
0.01
-90.95%
|
0.16
|
| Provisionand Write Offof Assets |
|
—
|
—
|
0.07
|
0.00
|
| Asset Impairment Charge |
|
0.04
|
0.00
|
0.00
+100.00%
|
-0.02
|
| Operating Gains Losses |
|
-0.00
-481.56%
|
0.00
|
—
|
0.10
|
| Gain Loss On Investment Securities |
|
-0.00
-481.56%
|
0.00
|
—
|
0.10
|
| Unrealized Gain Loss On Investment Securities |
|
0.07
|
0.00
-100.00%
|
0.00
-99.06%
|
0.33
|
| Change In Working Capital |
|
-1.18
-314.58%
|
0.55
+84.36%
|
0.30
+497.51%
|
-0.08
|
| Change In Receivables |
|
—
|
0.00
+100.00%
|
-0.00
+25.21%
|
-0.00
|
| Change In Prepaid Assets |
|
-0.12
-1194.75%
|
-0.01
-125.63%
|
0.04
-35.49%
|
0.06
|
| Change In Payables And Accrued Expense |
|
-0.99
-256.94%
|
0.63
+86.58%
|
0.34
+731.54%
|
-0.05
|
| Change In Payable |
|
—
|
—
|
0.34
+731.54%
|
-0.05
|
| Change In Account Payable |
|
—
|
—
|
0.34
+731.54%
|
-0.05
|
| Change In Other Working Capital |
|
-0.07
+0.00%
|
-0.07
+0.00%
|
-0.07
+0.00%
|
-0.07
|
| Investing Cash Flow |
|
0.64
-33.86%
|
0.97
+123.48%
|
-4.15
-4882.90%
|
0.09
|
| Cash Flow From Continuing Investing Activities |
|
0.64
-33.86%
|
0.97
+123.48%
|
-4.15
-4882.90%
|
0.09
|
| Capital Expenditure |
|
-0.57
|
—
|
—
|
—
|
| Net Investment Purchase And Sale |
|
1.22
+25.18%
|
0.97
+123.48%
|
-4.15
-6316.90%
|
0.07
|
| Purchase Of Investment |
|
-0.10
+44.91%
|
-0.18
+95.77%
|
-4.15
|
—
|
| Sale Of Investment |
|
1.32
+14.47%
|
1.15
|
0.00
-100.00%
|
0.07
|
| Net Intangibles Purchase And Sale |
|
-0.57
|
0.00
|
—
|
—
|
| Purchase Of Intangibles |
|
-0.57
|
0.00
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
0.02
|
| Financing Cash Flow |
|
4.86
+49.93%
|
3.24
+788.07%
|
-0.47
-109.54%
|
4.94
|
| Cash Flow From Continuing Financing Activities |
|
4.86
+49.93%
|
3.24
+788.07%
|
-0.47
-109.54%
|
4.94
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
3.73
+14.92%
|
3.24
+788.07%
|
-0.47
-109.54%
|
4.94
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.17
+63.26%
|
-0.47
|
0.00
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.17
+63.26%
|
-0.47
|
0.00
|
| Proceeds From Stock Option Exercised |
|
1.13
+37832666.67%
|
0.00
|
0.00
|
—
|
| Changes In Cash |
|
0.84
+120.95%
|
0.38
+104.86%
|
-7.84
-612.59%
|
1.53
|
| Beginning Cash Position |
|
3.91
+10.82%
|
3.52
-69.00%
|
11.37
+15.55%
|
9.84
|
| End Cash Position |
|
4.75
+21.58%
|
3.91
+10.82%
|
3.52
-69.00%
|
11.37
|
| Free Cash Flow |
|
-5.24
-36.58%
|
-3.83
-18.90%
|
-3.22
+7.81%
|
-3.50
|
| Interest Paid Supplemental Data |
|
0.04
+633.71%
|
0.01
+4.42%
|
0.00
+121.42%
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.03
|
| Common Stock Issuance |
|
3.73
+9.09%
|
3.41
|
0.00
-100.00%
|
4.94
|
| Issuance Of Capital Stock |
|
3.73
+9.09%
|
3.41
|
0.00
-100.00%
|
4.94
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-02 View
- 10-K2026-03-27 View
- 8-K2026-02-23 View
- 8-K2025-12-29 View
- 42025-12-16 View
- 42025-11-21 View
- 42025-11-20 View
- 10-Q2025-11-13 View
- 8-K2025-10-24 View
- 8-K2025-10-01 View
- 10-Q2025-08-13 View
- 8-K2025-08-05 View
- 8-K2025-07-29 View
- 8-K2025-07-10 View
- 8-K2025-07-03 View
- 42025-05-28 View
- 42025-05-27 View
- 42025-05-27 View
- 42025-05-27 View
- 42025-05-27 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|